Affimed Therapeutics, a biotech developing immunotherapies for lymphomas, leukemia and other cancers, raised $56 million by offering 8 million shares at $7, below the range of $11 to $13. Affimed Therapeutics plans to list on the NASDAQ under the symbol AFMD. Affimed Therapeutics initially filed confidentially on 5/23/2014. Jefferies & Co., Leerink Partners and BMO Capital Markets acted as lead managers on the deal.
